Health technology assessment (HTA) has been used to support healthcare decision making for high technology medicines in China. This article provides China’s experience in using HTA to support healthcare decision making on health insurance reimbursement for cancer immunotherapies. It explains assessment methods for decision making based on HTA methods and evidence. Main challenges on HTA application are identified. It also provides lesson learn China on HTA which can be useful for other countries dealing with challenges on financing of high technology medicines.
Using health technology assessment to inform decision making: an example of cancer immunotherapy
Reference
Yingyao Chen, Hengjin Dong, Yan Wei, Yi Yang, Jian Ming, and Hao Yu, Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy, BMJ, 15 Jun 2023
Published On
07 Sep 2024
Country
Tags
Source
Yingyao Chen, Hengjin Dong, Yan Wei, Yi Yang, Jian Ming, and Hao Yu, Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy, BMJ, 15 Jun 2023